NCT07123454 - A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2028

Conditions

B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

AZD4512

AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion

Trial Locations (17)

106

Research Site, Taipei

3000

Research Site, Melbourne

5505

Research Site, Seoul

10021

Research Site, New York

20133

Research Site, Milan

20141

Research Site, Milan

32224

Research Site, Jacksonville

37203

Research Site, Nashville

40138

Research Site, Bologna

44195

Research Site, Cleveland

55905

Research Site, Rochester

91010

Research Site, Duarte

113-8677

Research Site, Bunkyō City

135-8550

Research Site, Kōtoku

03080

Research Site, Seoul

NW1 2PG

Research Site, London

NE7 7DN

Research Site, Newcastle upon Tyne